Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome.

Department of Neurology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
European journal of pain (London, England) (Impact Factor: 3.37). 12/2009; 14(5):523-8. DOI: 10.1016/j.ejpain.2009.11.004
Source: PubMed

ABSTRACT Activated immune cells in the spinal cord may play an important role in the development and maintenance of neuropathic pain, such as occurs in response to peripheral inflammation or tissue injury. Immune activation may therefore serve as a therapeutic target for immune modulating drugs like corticosteroids. This double-blind randomized placebo-controlled parallel-group trial aimed to investigate the efficacy and safety of a single intrathecal administration of 60 mg methylprednisolone (ITM) in chronic patients with complex regional pain syndrome (CRPS). The primary outcome measure was change in pain (pain intensity numeric rating scale; range 0-10) after 6 weeks. With 21 subjects per group the study had a 90% power to detect a clinically relevant difference (> or = 2 points). After 21 patients (10 on ITM) were included, the trial was stopped prematurely after the interim analysis had shown that ITM had no effect on pain (difference in mean pain intensity numeric rating scale at 6 weeks 0.3, 95% confidence interval -0.7 to 1.3) or any other outcome measure. We did not find any difference in treatment-emergent adverse events between the ITM and placebo group. We conclude that a single bolus administration of ITM is not efficacious in chronic CRPS patients, which may indicate that spinal immune activation does not play an important role in this phase of the syndrome.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Methylprednisolone acetate (MPA) has a long history of use in the treatment of sciatic pain and other neuropathic pain syndromes. In several of these syndromes, MPA is administered in the epidural space. On a limited basis, MPA has also been injected intrathecally in patients suffering from postherpetic neuralgia and complex regional pain syndrome. The reports on efficacy of intrathecal administration of MPA in neuropathic pain patients are contradictory, and safety is debated. In this review, we broadly consider mechanisms whereby glucocorticoids exert their action on spinal cascades relevant to the pain arising after nerve injury and inflammation. We then focus on the characteristics of the actions of MPA in pharmacokinetics, efficacy, and safety when administered in the intrathecal space.
    Anesthesia and analgesia 05/2014; 118(5):1097-1112. · 3.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: SUMMARY Approximately 15% of patients with complex regional pain syndrome will experience no improvement in their condition within the first 12 months. This group should be considered as having a long-term condition. Recently published clinical studies and national guidelines can support clinicians to devise rational approaches to the management of this group; however, conclusive evidence is still lacking for almost all aspects of care. A multidisciplinary approach to managing long-standing complex regional pain syndrome appears best suited to ensure high-quality care. This should allow effective functional rehabilitation. Unfortunately, however, meaningful pain relief is often not achieved with currently available treatment methods. Recently published novel treatment approaches will probably provide more patients with long-term pain relief in the future, but confirmatory trials are required.
    Pain management. 03/2013; 3(2):137-46.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Complex Regional Pain Syndrome (CRPS) related dystonia, compelling evidence points at involvement of the central nervous system, but the underpinning pathobiology is still unclear. Thus, to enable a hypothesis-free, unbiased view of the problem and to get new insight into the pathobiology of dystonia in CRPS we have applied an exploratory metabolomics analysis of cerebrospinal fluid (CSF) of patients with CRPS related dystonia. (1)H-NMR spectroscopy in combination with multivariate modeling were employed to investigate metabolic profiles of a total of 105 CSF samples collected from patients with CRPS related dystonia and controls. We found a significantly different metabolic profile of CSF in CRPS patients as compared to controls. The differences are reflected already in the first two principle components of the PCA model which is an indication that the variance associated with CPRS is stronger than variance caused by such classical confounders as gender, age or individual differences. A supervised analysis generated a strong model pinpointing the most important metabolites contributed to the metabolic signature of patients with CRPS related dystonia. From the set of identified discriminators, the most relevant metabolites were 2-keto-isovalerate, glucose, glutamine, lactate, which all showed increased concentrations and urea which showed decreased concentration in CRPS subjects. Our findings point at a catabolic state in chronic CRPS patients with dystonia which likely is associated with inflammation.
    Pain 10/2013; · 5.64 Impact Factor